Jose L. Contelles-Marco

Madrid, MD, Spain

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 166 publications

Potent inhibition and limited reactivation of human cholinesterases by cholesterol- and quinoline-based oximes.

Potent inhibition and limited reactivation of human cholinesterases by cholesterol- and quinoline-based oximes.

Journal: Toxicology
Published: May 07, 2026

Polyfunctionalized N-Arylsulfonyl Indoles: Identification of (E)-N-Hydroxy-3-{3-[(5-(3-(piperidin-1-yl)propoxy]-1H-indol-1-yl)sulfonyl]phenyl}acrylamide (MTP150) for the Epigenetic-Based Therapy of Parkinson's Disease.

Polyfunctionalized N-Arylsulfonyl Indoles: Identification of (E)-N-Hydroxy-3-{3-[(5-(3-(piperidin-1-yl)propoxy]-1H-indol-1-yl)sulfonyl]phenyl}acrylamide (MTP150) for the Epigenetic-Based Therapy of Parkinson's Disease.

Journal: International journal of molecular sciences
Published: January 30, 2026

First Sustainable One-Pot Tandem Hantzsch Multicomponent Reaction/Click Reaction Approach for Novel Multitarget-Directed Ligands in Alzheimer's Disease.

First Sustainable One-Pot Tandem Hantzsch Multicomponent Reaction/Click Reaction Approach for Novel Multitarget-Directed Ligands in Alzheimer's Disease.

Journal: ACS chemical neuroscience
Published: December 29, 2025

Masupirdine, a Selective Serotonin 5‑HT6 Receptor Antagonist for Alzheimer's Disease.

Masupirdine, a Selective Serotonin 5‑HT6 Receptor Antagonist for Alzheimer's Disease.

Journal: ACS pharmacology & translational science
Published: December 23, 2025

Crosstalk between NLRP3 Signaling and Histone Deacetylases in Inflammasome-Driven Diseases.

Crosstalk between NLRP3 Signaling and Histone Deacetylases in Inflammasome-Driven Diseases.

Journal: Journal of medicinal chemistry
Published: December 23, 2025

NLRP3 Inflammasome Role and NLRP3 Inhibitors in Sensorineural Hearing Loss.

NLRP3 Inflammasome Role and NLRP3 Inhibitors in Sensorineural Hearing Loss.

Journal: Biomolecules
Published: November 18, 2025

Characterization of a Novel Family of Contilisant + Belinostat Multitarget Small Molecules in Glioblastoma.

Characterization of a Novel Family of Contilisant + Belinostat Multitarget Small Molecules in Glioblastoma.

Journal: Pharmaceuticals (Basel, Switzerland)
Published: November 04, 2025

Neuroprotective and Antioxidant Properties of Different Novel Steroid-Derived Nitrones and Oximes on Cerebral Ischemia In Vitro.

Neuroprotective and Antioxidant Properties of Different Novel Steroid-Derived Nitrones and Oximes on Cerebral Ischemia In Vitro.

Journal: International journal of molecular sciences
Published: October 29, 2025

Zervimesine, a Small Sigma‑2 Receptor Selective Modulator for Alzheimer's Disease.

Zervimesine, a Small Sigma‑2 Receptor Selective Modulator for Alzheimer's Disease.

Journal: ACS medicinal chemistry letters
Published: October 28, 2025

Generation and Characterization of Novel Contilisant+Tubastatin a Multitarget Small Molecules Against Glioblastoma.

Generation and Characterization of Novel Contilisant+Tubastatin a Multitarget Small Molecules Against Glioblastoma.

Journal: Pharmaceutics
Published: October 27, 2025

Multicomponent Synthesis of Multi-Target Quinazolines Modulating Cholinesterase, Oxidative Stress, and Amyloid Aggregation Activities for the Therapy of Alzheimer's Disease.

Multicomponent Synthesis of Multi-Target Quinazolines Modulating Cholinesterase, Oxidative Stress, and Amyloid Aggregation Activities for the Therapy of Alzheimer's Disease.

Journal: Molecules (Basel, Switzerland)
Published: September 01, 2025

Coinage Metal-Catalyzed Divergent Heterocyclizations of Underexplored N-Propargyl Hydrazides.

Coinage Metal-Catalyzed Divergent Heterocyclizations of Underexplored N-Propargyl Hydrazides.

Journal: Organic letters
Published: August 27, 2025
Showing 1-12 of 166

Last Updated: 09/26/2026